Mayne will now sell five products already on the shelves in the US with the company expecting material impact on revenue and profits to be immediate. Across the five products Mayne today acquires a licence for, Q3 CY2022 profits from those items alone stood at $25.1m. The currently weaker Australian dollar against the greenback is also a strong point of today’s deal.
Mayne Pharma has an extensive women’s health portfolio focused on contraceptives., page-2
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.65 |
Change
0.170(3.79%) |
Mkt cap ! $395.5M | |||
| Open | High | Low | Value | Volume |
| $4.50 | $4.68 | $4.47 | $1.532M | 331.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 206 | $4.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.65 | 262 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.61 |
Change
0.170 ( 2.41 %) |
||||
| Open | High | Low | Volume | ||
| $4.47 | $4.68 | $4.47 | 64875 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| MYX (ASX) Chart |